R
Rebecca Gardner
Researcher at Seattle Children's
Publications - 99
Citations - 7984
Rebecca Gardner is an academic researcher from Seattle Children's. The author has contributed to research in topics: Medicine & Chimeric antigen receptor. The author has an hindex of 23, co-authored 69 publications receiving 5367 citations. Previous affiliations of Rebecca Gardner include University of Washington & Seattle Children's Research Institute.
Papers
More filters
Journal ArticleDOI
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee,Rebecca Gardner,David L. Porter,Chrystal U. Louis,Nabil Ahmed,Michael C. Jensen,Stephan A. Grupp,Stephan A. Grupp,Crystal L. Mackall +8 more
TL;DR: A novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of C RS based on severity is presented, to maximize the chance for therapeutic benefit from the immunotherapy while minimizing the risk for life threatening complications of the syndrome.
Journal ArticleDOI
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,Jae H. Park,Elena Mead,Steven Z. Pavletic,William Y. Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Marcel R.M. van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
Journal ArticleDOI
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
Rebecca Gardner,Rebecca Gardner,Olivia Finney,Colleen Annesley,Colleen Annesley,Hannah Brakke,Corinne Summers,Corinne Summers,Kasey J. Leger,Marie Bleakley,Marie Bleakley,Christopher Brown,Stephanie Mgebroff,Karen S. Kelly-Spratt,Virginia Hoglund,Catherine Lindgren,Assaf P. Oron,Daniel Li,Stanley R. Riddell,Stanley R. Riddell,Julie R. Park,Julie R. Park,Michael C. Jensen,Michael C. Jensen,Michael C. Jensen +24 more
TL;DR: These data demonstrate that manufacturing a defined-composition CD19 CAR T cell identifies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profile in a cohort of patients with an otherwise poor prognosis.
Journal ArticleDOI
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner,David Wu,Sindhu Cherian,Min Fang,Laïla Aïcha Hanafi,Olivia Finney,Hannah Smithers,Michael C. Jensen,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +13 more
TL;DR: Administration of lymphodepletion chemotherapy followed by CD19-specific chimeric antigen receptor (CAR)-modified T cells is a remarkably effective approach to treating patients with relapsed and refractory CD19(+) B-cell malignancies.
ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
DW Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,JH Park,Elena Mead,Steven Z. Pavletic,WY Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Mrm van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: In 2018, the American Society for Blood and Marrow Transplantation (ASBMT) recognized the need to harmonize the definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity associated with CAR T cell therapies.